Refine by
Therapy Development Articles & Analysis
292 news found
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development of more effective cancer ...
With the advancement of biotechnology and biological tools, such as diagnostic technology and animal model development, researchers can further investigate the mechanisms related to depression and thereby develop effective therapies targeting depression. Ace Therapeutics Psychiatry Team is committed to supporting scientists in making ...
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. ...
By breaking down their diverse applications, this blog highlights the critical value of PCLS in addressing unmet needs in COPD research and therapy development. ...
As of the latest research, several experimental gene therapies for glaucoma are in various stages of development, from preclinical studies to early-phase clinical trials. ...
In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. Specializing in complex biologic formulations, Biologics & Biosimilars service team of CD Formulation is revolutionizing how drug conjugate products are ...
With extensive experience in the antipsychiatry industry, the Ace Therapeutics Psychiatry team understands the unique challenges and complexities of developing effective therapies for psychiatric disorders. By leveraging its expertise and resources, the company can develop animal models, cell models, multicellular models, ...
As cancer cases continue to rise across the globe, our understanding of the disease becomes more nuanced. Newer, more effective therapies are being developed each day, and data is becoming increasingly critical in diagnosis, therapy selection, and drug development. ...
Following with the announcement of developing small molecule drug for glaucoma, Ace Therapeutics recently unveiled disease model customization services to accelerate further the preclinical research on gastroenterology (GI) and hepatology. ...
At the same time, Alfa Cytology can also offer drug development services for pancreatic cancer with the data obtained from PC basic research. “The new drug development services focus on the hotspot of pancreatic tumor. We closely work with researchers to develop small molecule drugs and peptide drugs for PC as they are the most promising ...
(NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. ...
The availability of recombinant human collagen COL4 opens up new opportunities for researchers and clinicians in studying and developing therapies for diseases related to basement membrane dysfunction. Alfa Chemistry prides itself on providing high-quality recombinant human collagen products that meet the rigorous standards of research and ...
To help scientists better understand the regulation and role of mTOR in metabolic regulation and to address some of the major unanswered questions, CD BioSciences has developed a series of research solutions, empowering researchers to delve into the intricate world of metabolic signaling pathways. In addition, the company’s research team possesses the experience and ...
(OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire ...
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. ...
Our experienced team of CAR-T specialists can not only develop cutting-edge CAR-T therapies using advanced technologies, but also perform related biochemical evaluations." In the rapidly evolving field of drug delivery systems, novel therapies are continuously being developed to enhance the effectiveness and precision of ...
Beyond academic research and transplantation applications, CD Genomics' HLA typing solutions hold great promise in pharmaceutical drug development. They facilitate the identification of patient cohorts with specific HLA alleles, essential for developing targeted therapies. ...
SeqOne Genomics, provider of nextgeneration genomic analysis solutions for personalized medicine, announces the appointment of Hervé Pouzoullic as Chief Commercial Officer (CCO). He will lead the commercial development of the company to accelerate its growth and strengthen its international presence. Hervé has more than 25 years of experience in sales, business ...
The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy that has previously demonstrated clinical efficacy in healing VLUs that are resistant to standard treatments. ...
About ImmunogenX ImmunogenX, Inc. is a clinical-stage biopharmaceutical company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac ...